Development of novel regenerative medicine for congenital diseases using gene therapy biotechnology and embryonic stem cell

点击翻译按钮获取中文摘要

<Aim> Regenerative medicine and gene therapy may be the most promising therapeutics for many of congenital diseases. In this respect, a development of a novel biotechnology and therapeutic strategy is crucially necessary. The present study develops the following technology; 1) control to induce a target cell from embryonic stem (ES) cell, 2) certain purification of ES-derived target cells.<Results> 1. We developed a novel biotechnology that facilitated to certainly purify ES-derived target cells. 2. We developed a novel method that efficiently induced cardiomyogenic differentiation of ES cells using FGF-2 and BMP-2. 3. To further utilize this technology for future clinical application, we are doing research using human ES cells (our protocol was officially approved).<Future plan> 1. We will clone important genes using purified ES-derived target cells. 2. We will assess the therapeutic potential of our strategy. 3. We will continue this research using human ES cells as well as mouse ES cell.